Sangamo Therapeutics : Corporate Presentation

Pioneering the Future of Genomic Medicines

November 2022

Forward-Looking Statements

This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize durable, safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential to use ZFP, ZFP-TF,CAR-Treg and other technologies to develop durable, safe and effective therapies, the potential for us to benefit and earn milestone and royalty payments from our collaborations and the timing of any such benefits and payments, our cell therapy strategy, including expansion to additional indications, plans and timing regarding the expected resumption of dosing of patients in the Phase 3 AFFINE trial and the presentation of data from such trial, our financial resources, including the sufficiency thereof, our 2022 financial guidance, anticipated plans and timelines for us and our collaborators to enroll patients in and conduct clinical trials, dose and screen patients, and present clinical data, the anticipated advancement of our product candidates to late-stage development, including potential future Phase 3 trials, execution of our corporate strategy, our pipeline and the advancement of preclinical programs to the clinic, key milestones and catalysts, and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Our actual results may differ materially and adversely from those expressed. Factors that could cause actual results to differ include, without limitation, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of us and our collaborators, including the initiation and operation of clinical trials; the research and development process; the uncertain timing and unpredictable results of clinical trials, including whether preliminary or initial clinical trial data will be representative of final clinical trial data and whether final clinical trial data will validate the safety, efficacy and durability of product candidates; the impacts of clinical trial delays, pauses and holds on clinical trial timelines and commercialization of product candidates, including the risk that any necessary conditions to resume dosing of patients in the Phase 3 AFFINE trial of giroctocogene fitelparvovec are not met in a timely manner, or at all, including the risk that protocol amendments for the Phase 3 AFFINE trial of giroctocogene fitelparvovec may not be accepted by the relevant review bodies in a timely manner, or at all, which could further delay or preclude further patient dosing in this trial; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; the manufacturing of products and product candidates; the commercialization of approved products; the potential for technological developments that obviate technologies used by us and our collaborators; the potential for us or our collaborators to breach or terminate collaboration agreements; the potential for us to fail to realize our expected benefits of our collaborations; and the uncertainty of our future capital requirements, financial performance and results. There can be no assurance that we and our collaborators will be able to develop commercially viable products. These risks and uncertainties are described more fully in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as supplemented by our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. Forward-looking statements contained in this presentation speak only as of the date hereof, and we undertake no duty to update such information except as required under applicable law. This presentation concerns investigational product candidates that are under preclinical and/or clinical investigation and which have not yet been approved for marketing by any regulatory agency. They are currently limited to investigational use, and no representations are made as to their safety or efficacy for the purposes for which they are being investigated. Any discussions of safety or efficacy are only in reference to the specific results presented here and may not be indicative of an ultimate finding of safety or efficacy by regulatory agencies.

Non-GAAP Financial Measures

To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP total operating expenses, which exclude stock-based compensation expense from GAAP total operating expenses. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. We have excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business.

2

Leading Genomic Candidates into the Clinic

We are a genomic medicines company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious disease

Pioneer in	Multiple Clinical-stage	Advanced	In-house
Genomic Medicines	Programs	Scientific Toolkit	Manufacturing

3

Building a Genomic Medicines Company

Pioneering the Future

of Genomic Medicine

Early Learnings with

Breakthrough Technologies

1st	to edit endogenous
human genes
1st	to treat patients with
gene-editedT-cells
1st	to treat patients with in
	vivo genome editing
1st	to treat a patient with
engineered CAR-Tregs

Culture and

Track Record of Innovation

Advancing Differentiated

Genomic Medicines

through the Clinic

Leverage robust toolkit and expertise to advance pipeline

Focus on Hemophilia A, Fabry Disease, and Sickle Cell Disease

Pipeline of

First-Generation Genomic

Medicine Clinical Candidates

Expand utility of broad genomic engineering platform enabled by expertise in zinc fingers and CAR-Tregs

Deep pipeline of second- generation assets, focusing on autoimmune and neurology

Preclinical Pipeline Expansion

Utilizing Second-Generation

Genomic Engineering Platform

4

Value Thesis

01

First-generation product candidates for Fabry Disease, Sickle Cell Disease and Hemophilia A in or advancing into late- stage clinical development; provide insights for second-generation programs

02

Innovative second-generation candidates applying differentiated genomic medicine capabilities in cell therapy and genome engineering, with a focus in autoimmunity and neurology

03

Expansive R&D discovery engine

supported by long history of innovation

04

Five technology-validating blue chip biopharma partners offer domain expertise, up-frontpayments and a pathway to potential milestone payments

05

In-house cGMP manufacturing facilities provide control over

quality, supply, timelines, cost and IP

06

Strong financial position to take us through our key upcoming expected catalysts

5